Beacon Therapeutics has found the light in a rare vision loss disease that has left larger companies in the dark. The biotech’s gene therapy for X-linked retinitis pigmentosa (XLRP) successfully improved visual acuity in a pivotal trial, setting up the startup to seek regulatory approval.
